![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » TOYAMA LAUNCHES RHEUMATOID ARTHRITIS TRIALS
TOYAMA LAUNCHES RHEUMATOID ARTHRITIS TRIALS
Japan-based Toyama Chemical has begun Phase I clinical trials of T-5224, its proprietary drug candidate for the treatment of rheumatoid arthritis (RA).
A low-molecular compound that inhibits an activator protein 1 (AP-1), T-5224 alleviates inflammation and joint destruction so it is expected to be used as a basic remedy for RA.
The development of the drug has been sponsored by the Japan Science and Technology Agency, the company said.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct